Mark Joseph Buchfuhrer MD
Pleural Disease, Sleep Medicine
Consulting Assistant Professor, Stanford University School of Medicine
Join to View Full Profile
11480 Brookshire Avenue# 108Downey, CA 90241
Phone+1 562-904-1101
Fax+1 562-904-1105
Dr. Buchfuhrer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 1980 - 1981
University of Ottawa Faculty of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 1979 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Clinical Trials
- A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS Start of enrollment: 2023 Nov 15
Roles: Contact
Publications & Presentations
PubMed
- 4 citationsAdjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial.Mark J Buchfuhrer, Asim Roy, Stephanye Rodriguez, Jonathan D Charlesworth
BMC Neurology. 2023-11-21 - 7 citationsBilateral high-frequency noninvasive peroneal nerve stimulation evokes tonic leg muscle activation for sleep-compatible reduction of restless legs syndrome symptoms.Jonathan D Charlesworth, Bahman Adlou, Haramandeep Singh, Mark J Buchfuhrer
Journal of Clinical Sleep Medicine. 2023-07-01 - 9 citationsNoninvasive neuromodulation reduces symptoms of restless legs syndromeMark J. Buchfuhrer, Fiona C. Baker, Haramandeep Singh, Viktoriia Kolotovska, Bahman Adlou
Journal of Clinical Sleep Medicine. 2021-08-01
Press Mentions
AASM’s New RLS Guidelines Recommend Peroneal Nerve Stimulation TherapyOctober 8th, 2024- Noctrix Health Secures $40 Million Series C Financing to Commercialize Novel Device Treatment for Restless Legs Syndrome (Rls)August 19th, 2024
- Noctrix Health Announces Enrollment of First Patient in the RESTFUL Study and Publication of Positive Pilot Study ResultsMay 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
